Intl Stem Cell Corp (ISCO) 0.0950 $ISCO
International Stem Cell Corporation to Present at Two Upcoming Investment Conferences
Marketwire - Thu Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.
International Stem Cell Corporation Provides R&D and Business Results for Second Quarter and First Half of 2014
Marketwire - Tue Aug 12, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results for the three and six months ended June 30, 2014.
International Stem Cell Corporation to Host Second Quarter 2014 Business Update and Financial Results Conference Call at 11:00 am ET on Tuesday, August 12, 2014
Marketwire - Thu Aug 07, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Tuesday, August 12, 2014 to provide a business update and discuss its financial results for the three and six months ended June 30, 2014.
International Stem Cell Corporation Launches Stroke Program With Tulane University
Marketwire - Tue Aug 05, 7:33AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell based therapies, announced today that it has launched a new Stroke Program. Together with Tulane University, ISCO will study the impact of human parthenogenetic neural stem cells (hpNSC) transplantation in a pre-clinical rodent model of ischemic stroke as a first step toward the clinical development of a potential stroke treatment. The proof-of-concept study will be done in the laboratory of Dr. Jean-Pyo Lee, a well-known expert in the field of regenerative medicine.
International Stem Cell Corporation Secures Approval for Core Technology Patents in European Union
Marketwire - Tue Jul 22, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell based therapies and biomedical products, received formal opinion from the Advocate General for the European Union Court of Justice (CJEU) in favor of the Company's pending core technology patents.
Lifeline Cell Technology Expands Asian Distribution Network
Marketwire - Wed Jul 16, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company focused on therapeutic and research products, today announced that its subsidiary, Lifeline Cell Technology, has expanded its sales network by adding a number of new distributors in Asia and Oceania.
International Stem Cell Corporation Signs Agreement Including Certain Terms for a Definitive License Agreement With Rohto Pharmaceutical Co., Ltd. of Japan
Marketwire - Tue Jul 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com, ISCO or the Company), a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a research agreement with Rohto Pharmaceutical Co., Ltd. ("Rohto" , a global Japanese pharmaceutical company that develops new technology for the medical and cosmetics markets with approximately $1.3 billion in consolidated annual sales. Under this agreement, Rohto will evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is anticipated that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. Certain key terms of such a license agreement, including the target disease areas and intellectual property rights, have been established in the research agreement.
International Stem Cell Corporation Completes Important Study in Parkinson's Disease Program
Marketwire - Thu Jun 19, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell based therapies, announced today the completion of the acute toxicity study of the Company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The Company intends to provide a further update early next quarter.
International Stem Cell Corporation to Present at BIO 2014
Marketwire - Tue Jun 17, 2:24PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw, will present an overview of ISCO and its subsidiaries at the BIO 2014 conference on Tuesday, June 24th at 4:15 pm PDT. The conference is being held at the San Diego Convention Center.
Lifeline Skin Care Expands Into Latin America's Second Largest Market
Marketwire - Tue Apr 01, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that Lifeline Skin Care, its operating subsidiary, has signed a distribution agreement with Grupo Venta Internacional, S.A de C. V., Mexico's largest distributor of aesthetic and reconstructive products. Effective immediately, Grupo Venta Internacional will offer Lifeline's breakthrough stem cell skin care products to health care professionals throughout Mexico, the second largest market for aesthetic skin care in Central and South America.
International Stem Cell Corporation Announces 2013 Fourth Quarter and Year-End Results
Marketwire - Tue Mar 18, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the year ended December 31, 2013.
International Stem Cell Corporation to Host Full-Year 2013 Business Update and Financial Results Conference Call Wednesday, March 19, 2014
Marketwire - Thu Mar 13, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products announced today that management will host a conference call on Wednesday, March 19, 2014 to provide a business update and discuss its financial results for the year ended December 31, 2013.
Odemwingie Pleased With Stoke Debut
All Africa Global Media - Tue Feb 04, 4:56AM CST
Out of favour Super Eagles forward, Osaze Peter Odemwingie has spoken of his delight following his Barclays English Premier League debut for Stoke City last weekend. Odemwingie completed an 18-month move to the Britannia Stadium on January 28 and was immediately thrown into the deep end by the Stoke Manager, Mark Hughes, against Manchester United on Saturday.
International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage
Marketwire - Mon Sep 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, announced today further progress in its Parkinson's disease program with a recently held key opinion leader meeting facilitated by the study's principal investigator, Dr. Mark Stacy of Duke Medicine.
International Stem Cell Corporation to Present at Rodman & Renshaw 15th Annual Global Investment Conference September 8th to 10th
Marketwire - Wed Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will participate in Rodman & Renshaw's 15th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program
Marketwire - Wed Aug 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product.
International Stem Cell Corporation Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced financial results for the three and six months ended June 30, 2013.
Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation
Marketwire - Tue Aug 06, 7:30AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Friday, August 9, 2013
Marketwire - Thu Aug 01, 4:00PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, August 9, 2013 to discuss its financial results for the three and six months ended June 30, 2013.
International Stem Cell Corporation to Present at Two Upcoming Investment Conferences
Marketwire - Thu Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw will present a corporate overview of ISCO and its subsidiaries at two upcoming investment conferences.
International Stem Cell Corporation Provides R&D and Business Results for Second Quarter and First Half of 2014
Marketwire - Tue Aug 12, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell based therapies and biomedical products today provided a business update and announced financial results for the three and six months ended June 30, 2014.
International Stem Cell Corporation to Host Second Quarter 2014 Business Update and Financial Results Conference Call at 11:00 am ET on Tuesday, August 12, 2014
Marketwire - Thu Aug 07, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Tuesday, August 12, 2014 to provide a business update and discuss its financial results for the three and six months ended June 30, 2014.
International Stem Cell Corporation Launches Stroke Program With Tulane University
Marketwire - Tue Aug 05, 7:33AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell based therapies, announced today that it has launched a new Stroke Program. Together with Tulane University, ISCO will study the impact of human parthenogenetic neural stem cells (hpNSC) transplantation in a pre-clinical rodent model of ischemic stroke as a first step toward the clinical development of a potential stroke treatment. The proof-of-concept study will be done in the laboratory of Dr. Jean-Pyo Lee, a well-known expert in the field of regenerative medicine. International Stem Cell Corporation Secures Approval for Core Technology Patents in European Union
Marketwire - Tue Jul 22, 7:32AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell based therapies and biomedical products, received formal opinion from the Advocate General for the European Union Court of Justice (CJEU) in favor of the Company's pending core technology patents. Lifeline Cell Technology Expands Asian Distribution Network
Marketwire - Wed Jul 16, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company focused on therapeutic and research products, today announced that its subsidiary, Lifeline Cell Technology, has expanded its sales network by adding a number of new distributors in Asia and Oceania. International Stem Cell Corporation Signs Agreement Including Certain Terms for a Definitive License Agreement With Rohto Pharmaceutical Co., Ltd. of Japan
Marketwire - Tue Jul 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com, ISCO or the Company), a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a research agreement with Rohto Pharmaceutical Co., Ltd. ("Rohto"
, a global Japanese pharmaceutical company that develops new technology for the medical and cosmetics markets with approximately $1.3 billion in consolidated annual sales. Under this agreement, Rohto will evaluate stem cell-derived human cells owned and provided by ISCO in a number of pre-clinical animal models. If the research is successful and the parties agree on remaining terms, it is anticipated that a definitive license agreement will be signed at the end of the twelve-month period of this research agreement. Certain key terms of such a license agreement, including the target disease areas and intellectual property rights, have been established in the research agreement. International Stem Cell Corporation Completes Important Study in Parkinson's Disease Program
Marketwire - Thu Jun 19, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell based therapies, announced today the completion of the acute toxicity study of the Company's proposed clinical product to treat Parkinson's disease. The recently completed IND-enabling study transplanting rodents with human neural stem cells, derived from ISCO's proprietary parthenogenetic stem cell platform, showed that the cells are well tolerated even at high doses up to the equivalent of 2.2 billion cells in humans. The program continues to progress according to the plan outlined with the FDA at the pre-IND meeting as reported in February 2014. The Company intends to provide a further update early next quarter. International Stem Cell Corporation to Present at BIO 2014
Marketwire - Tue Jun 17, 2:24PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced that Executive Vice President Dr. Simon Craw, will present an overview of ISCO and its subsidiaries at the BIO 2014 conference on Tuesday, June 24th at 4:15 pm PDT. The conference is being held at the San Diego Convention Center.
Lifeline Skin Care Expands Into Latin America's Second Largest Market
Marketwire - Tue Apr 01, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that Lifeline Skin Care, its operating subsidiary, has signed a distribution agreement with Grupo Venta Internacional, S.A de C. V., Mexico's largest distributor of aesthetic and reconstructive products. Effective immediately, Grupo Venta Internacional will offer Lifeline's breakthrough stem cell skin care products to health care professionals throughout Mexico, the second largest market for aesthetic skin care in Central and South America.
International Stem Cell Corporation Announces 2013 Fourth Quarter and Year-End Results
Marketwire - Tue Mar 18, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the year ended December 31, 2013. International Stem Cell Corporation to Host Full-Year 2013 Business Update and Financial Results Conference Call Wednesday, March 19, 2014
Marketwire - Thu Mar 13, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products announced today that management will host a conference call on Wednesday, March 19, 2014 to provide a business update and discuss its financial results for the year ended December 31, 2013.
Odemwingie Pleased With Stoke Debut
All Africa Global Media - Tue Feb 04, 4:56AM CST
Out of favour Super Eagles forward, Osaze Peter Odemwingie has spoken of his delight following his Barclays English Premier League debut for Stoke City last weekend. Odemwingie completed an 18-month move to the Britannia Stadium on January 28 and was immediately thrown into the deep end by the Stoke Manager, Mark Hughes, against Manchester United on Saturday.
International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage
Marketwire - Mon Sep 09, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell-based therapies, announced today further progress in its Parkinson's disease program with a recently held key opinion leader meeting facilitated by the study's principal investigator, Dr. Mark Stacy of Duke Medicine.
International Stem Cell Corporation to Present at Rodman & Renshaw 15th Annual Global Investment Conference September 8th to 10th
Marketwire - Wed Aug 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that it will participate in Rodman & Renshaw's 15th Annual Global Investment Conference sponsored by H.C. Wainwright & Co., LLC. The conference is being held September 8-10, 2013, at the Millennium Broadway Hotel in New York City.
International Stem Cell Corporation Enters Into Clinical Research Agreement for Parkinson's Disease Program
Marketwire - Wed Aug 21, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with Duke University to conduct clinical trials research in Parkinson's disease using ISCO's innovative neural stem cell product.
International Stem Cell Corporation Announces Second Quarter 2013 Financial Results
Marketwire - Thu Aug 08, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"
, a California-based biotechnology company developing novel stem cell based therapies and biomedical products, today announced financial results for the three and six months ended June 30, 2013. Crystal Research Associates, LLC Issues Executive Informational Overview (EIO) on International Stem Cell Corporation
Marketwire - Tue Aug 06, 7:30AM CDT
Crystal Research Associates, LLC announced today that it has issued an Executive Informational Overview(R) (EIO) on International Stem Cell Corporation (OTCQB: ISCO). The full 72-page report is available on Crystal Research Associates' website at www.crystalra.com.
International Stem Cell Corporation to Host Second Quarter 2013 Financial Results Conference Call at 11:00 a.m. ET on Friday, August 9, 2013
Marketwire - Thu Aug 01, 4:00PM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a California-based biotechnology company developing novel stem cell based therapies and biomedical products announced today that it will host a conference call on Friday, August 9, 2013 to discuss its financial results for the three and six months ended June 30, 2013.
